Commercializing the Microbiome – the Unseen Organ

Wednesday, Mar 21, 2018

Only 80 seats available. Registration closes March 20 or when we sell out.

700 Main Street, Cambridge, MA
6:00PM -8:30PM
$35 GABC Members
$45 Non-Members

Calendar Link


If you are a member, you should sign in to take advantage of member pricing, and your checkout details will be filled automatically.

Number of tickets:

Total: $0

Pay by check

The vast majority of your body’s bacteria reside in your gut. These bacteria (microbes), live inside and on any tissue of your body (including your gut), exerting a profound impact on your health and just about every bodily process. This is your microbiome.

Allergies, autoimmunity, depression and other inflammatory diseases are increasing at alarming rates and have all been associated with impaired microbiome health.

This evening will be all about the microbiome — how exactly does it influence our lifestyle and well-being? Why is it relevant in drug development and for which therapeutic areas does it have the most potential?

Please join us at LabCentral in the heart of Kendall Square’s innovation district, as we explore the significance of the microbiome and its commercial value. What is fact and what is fiction? A diverse set of speakers from Big Pharma and rising new stars from the biotech startup world will talk about their vision for the microbiome.

Keynote Speakers

  • Alex Tucker is the Program Lead at Ginkgo Bioworks, a Boston-based synthetic biology company that makes and sells engineered organisms.
  • Dean Falb, PhD is Chief Technology Officer and Founder of Synlogic Therapeutics, a venture-backed start-up company in the human microbiome space.


  • Azza A.Gadir, PhD (Moderator) is a postdoctoral scientist working on the Immunological mechanisms that underly food allergy at Harvard University/Boston Childrens’ Hospital.
  • Arpita Maiti, PhD is Senior Director, External Science & Innovation (ES&I) at Pfizer where she  is a member of the external opportunities (discovery to Proof of Concept) search and evaluation team for Inflammation & Immunology.
  • Bernat Olle  is Chief Executive Officer and Co-founder of ‎Vedanta Biosciences, Inc. which is developing a novel class of therapies based on bacterial consortia that modulate interactions between the human microbiome and the host immune system.
  • Philip Strandwitz,PhD, is Co-Founder and CEO, Holobiome which translates microbiome science into novel therapeutics to treat diseases of the central and enteric nervous systems. He is a specialist in the microbiome, with a focus on the gut-brain-axis.


Wednesday, March 21, 2018
Time: 6:00PM – 8:30PM


700 Main Street, North
Cambridge, MA 02139
A 70,000 square-foot facility in the heart of the Kendall Square biotech innovation hub, LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for as many as 60 startups comprising approximately 200 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support that early-stage companies need to begin laboratory operations on day one.

Public Trans: Kendall T Station
Parking: metered street parking

This event sponsored by Bayer LifeHub Boston
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture.  LifeHub Boston believes that creating breakthrough solutions to global health challenges requires creative thinking and radical collaboration across industries and mindsets.

This event is organized by GABC with the following event partners

  • British American Business Council of New England (BABCNE)
  • Bayer LifeHub Boston
  • German Accelerator Life Sciences (GALS)
  • Swedish American Chamber of Commerce New England (SACC-NE)
  • LabCentral

Want to get an invitation?  Get on our mailing list!  Email with “add to mailing list” in the subject line.